At a Special Meeting of Stockholders on June 23, 2026, Profusa, Inc. stockholders approved several key measures. These include authorizing the Board of Directors to execute one or more reverse stock splits between 1-for-5 and 1-for-200 through June 23, 2028. Stockholders also approved the issuance of convertible preferred stock to Bio Insights LLC for the acquisition of PanOmics Assay assets, the potential issuance of common stock exceeding 19.99% of outstanding shares upon conversion of a promissory note to NorthView Sponsor I LLC, and increasing the 2025 Equity and Incentive Plan share pool by 695,544 shares to a total of 795,930. Additionally, Lauren Chung was elected as a Class I director. The company operates in the biotechnology industry, developing sensing technologies for health monitoring.
